Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Britain Courts Anthropic Amid US Defense Department Dispute 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple Turns 50: From Garage Startup to AI Crossroads 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
ST. LOUIS PARK, Minn., July 10, 2017 -- NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of Andrew ElBardissi, M.D. to its Board of Directors, effective immediately. Dr. ElBardissi is replacing Avi Kometz, MD as the representative from Deerfield Management on the NeoChord Board of Directors.
“We are pleased to add Andrew to our Board of Directors, and we look forward to his strategic guidance. With his experience in early stage medical technology development, cardiothoracic surgery and research, Andrew will be of great benefit to the company as we continue progress with our US clinical trial,” said David Chung, President and Chief Executive Officer. “Avi has been an integral part of NeoChord over the past few years, and we are thankful for his partnership and many contributions.”
“I am delighted to join an organization leading the way in minimally invasive treatment of structural heart disease,” said Andrew ElBardissi, “I am looking forward to providing guidance as a member of the Board of Directors as the company continues to excel with their world class clinical, commercial and R&D programs."
Dr. ElBardissi has significant investment experience in the healthcare sector. He is currently an investor on the Private Transactions team at Deerfield Management Company and has previously held roles as an early stage life-sciences venture investor and investment banker. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and as presented his research at numerous medical and surgical conferences.
About NeoChord, Inc.
Founded in 2007 and based in St. Louis Park, Minnesota, NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for DMR. NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the FDA for the US pivotal trial in May 2016. For more information, please visit the Company's website at www.neochord.com.
The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
NEOCHORD, DS1000, RECHORD, the stylized logos, and Transforming Mitral Valve Repair are registered trademarks or service marks of the NeoChord Corporation.
Contact: Bruce Van Deman NeoChord, Inc. (952) 698-7812 or (949) 413-1301 [email protected]
